Swing Trading Opportunity: Amgen (AMGN) Dividend Play ($2.13 per share) on June 08, 2023.
Swing trading involves capturing short-term price movements in stocks, and taking advantage of market fluctuations. In this article, we will analyze Amgen (AMGN), a high-capitalization stock, and explore a potential swing trading opportunity surrounding its upcoming dividend payment. By understanding the dividend schedule and its implications for traders, we can assess the potential for capitalizing on this event.
Amgen (AMGN) has announced a dividend payment of $2.13 per share, scheduled to be paid on June 08, 2023. The record date for this dividend is also June 08, 2023, while the ex-dividend date is set for May 17, 2023. It is important to note that the ex-dividend date is typically set a few business days before the record date.
For swing traders interested in Amgen (AMGN), the ex-dividend date is a crucial factor to consider. The ex-dividend date serves as a cut-off point determining who is entitled to receive the upcoming dividend payment. If shares are purchased on or after the ex-dividend date (May 17, 2023, in this case), the buyer will not be eligible to receive the dividend payment. Instead, the dividends are retained by the seller. However, if the stocks are purchased before the ex-dividend date, the buyer will be entitled to receive the dividend.
AMGN in upward trend: 10-day moving average moved above 50-day moving average on October 07, 2025
The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on October 07, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 17, 2025. You may want to consider a long position or call options on AMGN as a result. In of 70 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for AMGN just turned positive on September 30, 2025. Looking at past instances where AMGN's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
AMGN moved above its 50-day moving average on October 01, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in of 301 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AMGN broke above its upper Bollinger Band on October 20, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AMGN entered a downward trend on September 30, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.459) is normal, around the industry mean (9.693). P/E Ratio (24.201) is within average values for comparable stocks, (24.251). Projected Growth (PEG Ratio) (0.960) is also within normal values, averaging (1.906). Dividend Yield (0.032) settles around the average of (0.028) among similar stocks. P/S Ratio (4.585) is also within normal values, averaging (3.519).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock slightly better than average.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. AMGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of human therapeutic products based on cellular biology
Industry PharmaceuticalsMajor
Advertisement